Idera Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IDRA research report →
Price Chart
About the company
Idera Pharmaceuticals, Inc. is a biopharmaceutical company committed to the research, development, and commercialization of medicines addressing rare diseases within the United States. A key offering is Tilsotolimod (IMO-2125), a proprietary synthetic phosphorothioate oligonucleotide.
- CEO
- Vincent J. Milano
- IPO
- 1996
- Employees
- 13
- HQ
- Exton, PA, US
Get TickerSpark's AI analysis on IDRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- -0.06
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.12
- EV/EBITDA
- 0.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -113.18%
- ROIC
- -27.40%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-27,818,000
- Net Income
- $-23,360,000-123.8%
- EPS
- $-7.18-122.8%
- OCF Growth
- +0.4%
- FCF Growth
- +0.4%
- 52W High
- $16.00
- 52W Low
- $0.42
- 50D MA
- $6.25
- 200D MA
- $7.36
- Beta
- 0.00
- RSI (14)
- 50
- Avg Volume
- 34.02K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Idera said its tilsotolimod program is progressing ahead of plan, with 204 showing encouraging early activity and 301 being resized to improve the odds of a successful registrational readout.· August 8, 2019
- 301 enrollment was already at 294 patients, ahead of the original 308 target, but the company increased the goal to about 450 after revising efficacy assumptions.
- 204 showed 27% overall response rate in 49 efficacy-evaluable patients, with 74% achieving stable disease or better and median overall survival not yet reached.
- Management said FDA did not object to the 301 design changes, including the lower efficacy assumptions and larger sample size.
- The company plans to start 206 this quarter, beginning with microsatellite stable colorectal cancer, then head and neck cohorts.
- Cash and investments of $52.4 million were said to fund operations into the second quarter of 2020.
For the quarter ended June 30, 2019, revenue was $1.4 million versus $200,000 a year ago. R&D expense was $10.0 million versus $10.9 million in the prior-year period, and G&A expense was $2.9 million versus $4.0 million. Net loss applicable to common stockholders was $11.2 million, or $0.39 per basic and diluted share, compared with $16.0 million, or $0.59 per share, last year. As of June 30, 2019, cash, cash equivalents and short-term investments were $52.4 million, which management said should fund operations into the second quarter of 2020; guidance for 301 was updated to an enrollment goal of approximately 450 patients, with completion of randomization expected in the first half of next year, and 204 data suggesting 27% ORR in 49 evaluable patients, 74% disease control rate, and median OS not yet reached.
Vincent Milano emphasized execution and said the team had advanced tilsotolimod rapidly through the first pivotal trial and into additional tumor-type exploration. He framed the 301 changes as improving the probability of success and said the program is aimed at patients with very limited treatment options. His tone was confident and promotional about the asset, but he also noted the company is small and resource-constrained, stressing discipline and focus.
John Kirby said the quarter’s operating costs were down year over year, with R&D at $10.0 million and G&A at $2.9 million, helped by lower employee and facility costs after the Cambridge site closure and because the prior-year quarter included $1.6 million of merger-related costs. He reported net loss of $11.2 million, or $0.39 per share, and said revenue was $1.4 million. On liquidity, he said the $52.4 million cash balance, cash equivalents and short-term investments should fund operations into the second quarter of 2020, with additional flexibility through Lincoln Park Capital and JMP Securities and a continued disciplined approach to spending.
Analysts focused on how sick the 204 patients were, how that compares with 301, and whether the 204 response rate can be translated to the Phase III setting. Management said 204 included more difficult ECOG 2 patients, while 301 excludes ECOG 2, so 301 could potentially show better ORR. Questions on the 301 interim analysis and accelerated approval were answered by saying the study includes an interim analysis intended to support no survival detriment versus ipilimumab alone, and FDA did not object to the proposed amendment or the lower ORR benchmark of a 10 percentage point improvement.
The positive case from the call is that tilso appears to be showing activity in a hard-to-treat melanoma population, with 27% ORR, 74% disease control and durable responses in 204. Management also said 301 enrollment has been ahead of schedule and that the design changes were supported by outside experts and not objected to by the FDA, which they believe raises the odds of a successful registrational outcome.
The main risks discussed were that 301’s prior efficacy assumptions were too aggressive, forcing a larger trial and potentially pushing data later, with completion now expected in the first half of next year and readout 9 to 12 months after the last patient is enrolled. Cash resources are limited, with funding only into the second quarter of 2020, and the company still needs to prove that the encouraging 204 activity will translate into a registrational benefit in the cleaner Phase III population.
AI summary of the company's earnings call · Paraphrased · Not investment advice
of shares held by institutions
28 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aperio Group, LLC | 21.10K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 10, 23 | GOWEN MAXINE | sell | 51 |
| Aug 10, 23 | MILANO VINCENT | sell | 3,283 |
| May 17, 23 | Pillar Invest Corp | buy | 26,965 |
| Jul 12, 23 | Pillar Invest Corp | sell | 3,605 |
| Jul 13, 23 | Pillar Invest Corp | sell | 2,213 |
| May 15, 23 | Chopra Atul | sell | 6,887 |
| May 15, 23 | Chopra Atul | sell | 6,645 |
| May 15, 23 | Chopra Atul | sell | 8,469 |
| May 15, 23 | Chopra Atul | sell | 1,220 |
| May 15, 23 | Chopra Atul | sell | 3,369 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IDRA coverage
Recent articles, reports, and earnings notes.
No research on IDRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IDRA report →Energy Recovery Wins “Breakthrough Innovation Award” at IDRA World Congress
businesswire.com · Dec 16
Buying Penny Stocks Right Now? 3 Top Tips to Know
pennystocks.com · May 21
3 Penny Stocks That Are Climbing During Today's Market Selloff
pennystocks.com · May 18
Why Are Idera Pharmaceuticals Shares Soaring Today
benzinga.com · May 17
5 Top Biotech Penny Stocks Under $1 To Watch This Week
pennystocks.com · Apr 19
Hot Penny Stocks For 2022 To Buy For Under $2
pennystocks.com · Jan 4
5 Penny Stocks To Buy According To Analysts & Targets Up To 341%
pennystocks.com · Dec 8
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
globenewswire.com · Aug 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.